Adial Pharmaceuticals(ADIL)

Focus: Adial Pharmaceuticals is a publicly traded specialty pharma company focused on addiction treatment, specifically repurposing ondansetron for alcohol use disorder. The company operates at micro-cap scale with minimal revenue generation and approximately $4M cash on hand.

Neurology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Adial Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Adial Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Ondansetron

Alcohol Use Disorder

Pre-Revenue

Repurposed 5-HT3 antagonist in Phase 3; no approved product or commercial revenue to date.

Pipeline & Clinical Trials

Help build intelligence for Adial Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Single late-stage asset (ondansetron Phase 3 for AUD) provides focused mission with clear near-term value inflection if successful
Emerging market: addiction treatment is a high-unmet-need area with growing regulatory priority and insurance coverage expansion
Public company status enables equity upside potential for early employees if Phase 3 trial succeeds

Watch Out For

Severe financial distress: $13.2M net loss in FY2025 against only $4M cash reserves signals runway of <4 months at current burn rate
Zero open job postings and minimal headcount indicate skeleton crew with limited growth or career mobility
Single-asset pipeline with no Phase 1 or Phase 2 programs creates binary outcome risk; Phase 3 failure could trigger insolvency

Generated by Claude from Adial Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ondansetron

Alcohol Use Disorder

Phase 3

Clinical Trials (1)

NCT04101227Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2010

Portfolio: 1 clinical trial

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

R&D Spend

$3M155%

Net Income

-$13M

Cash

$4M

Source: SEC 10-K Filing